Zydus Group in the news
Healthcare therapies manufacturing and marketing
Tamtam found 20 recent articles about Zydus Group.
- USFDA Inspection at Zydus' LiqMeds UK: 4 Observations
USFDA found four observations during an inspection at Zydus Lifesciences' LiqMeds facility in the UK.
- SAIL, Zydus apply to set up global treasury centres at GIFT City
SAIL and Zydus Group are setting up global treasury centres at GIFT City to centralize their financial operations, joining other major Indian corporations in leveraging the IFSC for efficient treasury management.
- शेयर बाजार की तेजी में 6 बड़ी कंपनियो के शेयर नए 52 वीक हाई पर पहुंचे, इनमें Coforge और Eternal भी शामिल
On November 3rd, six major companies, including Zydus Lifesciences, reached new 52-week stock price highs amidst a surging stock market.
- Stocks to Watch: बुधवार को इन 11 शेयरों पर रहेगी नजर, Zydus से Hyundai तक मंगलवार की शाम आईं खबरें
Several companies, including Zydus Lifesciences, Hyundai Motor, GTPL Hathway, JK Tyre, and Aarti Industries, released significant news ranging from USFDA observations and investment plans to financial results and new business agreements, which are expected to influence their stock performance.
- Zydus Therapeutics presents Phase 3 saroglitazar data at ACG 2026
Zydus Therapeutics presented Phase 3 data at ACG 2026 for its investigational drug saroglitazar, showing a greater biochemical response in US patients with primary biliary cholangitis than in non-US patients.
- Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC
Zydus Therapeutics announced new analysis from its Phase 3 trial showing saroglitazar had a greater biochemical response for primary biliary cholangitis compared to placebo, particularly in the U.S. subgroup.
- Zydus, MSN launch generic Adempas
Zydus and MSN launched the first generic version of Adempas (riociguat) tablets in the U.S., indicated for treating specific types of pulmonary hypertension.
- Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.
Zydus Lifesciences and MSN Laboratories launched the first generic riociguat tablets in the U.S. for pulmonary hypertension.
- Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.
Zydus and MSN Laboratories launched the first generic version of Adempas® (riociguat tablets) in the U.S. for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
- Zydus Lifesciences: अमेरिकन मार्केटमध्ये मोठी झेप, 'Adempas' चे पहिले जेनेरिक व्हर्जन लाँच
Zydus Lifesciences launched the first generic version of Riociguat tablets in the US market for pulmonary hypertension, a drug that generated around $850 million in global sales for its branded counterpart.
- Zydus Life USFDA inspection at Ahmedabad plant concludes with 1 observation
Zydus Lifesciences faced one observation from a USFDA inspection at its Ahmedabad plant, while another inspection in New Jersey had no observations, alongside recent product approvals and mixed Q1 financial results.
- Zydus Lifesciences gains 2%, hits 52-week high in weak market; here's why
Zydus Lifesciences' stock reached a 52-week high after a positive USFDA inspection and continued strong business growth in India and international markets.
- Zydus New Jersey Office Completes USFDA Pharmacovigilance Inspection With Nil Observations
Zydus Lifesciences' New Jersey office passed a USFDA pharmacovigilance inspection with no observations.
- Zydus Gets USFDA Approval For Ascorbic Acid Injection With 180-Day Exclusivity
Zydus Lifesciences gained USFDA approval for its generic Ascorbic Acid Injection, securing potential 180-day market exclusivity and expanding its US generic pharmaceutical portfolio.
- Zydus Deal Drops Mereo A Lifeline For Rare Disease Candidate Alvelestat
Sentynl Therapeutics acquired US commercial and global manufacturing rights to alvelestat, a drug for AATD-LD, from Mereo BioPharma, involving up to $475 million in payments.
- Sandeep Majumdar Joins Zydus Group as Executive Vice President, Biologics Operations
Zydus Group appointed Sandeep Majumdar as Executive Vice President, Biologics Operations to lead manufacturing excellence.
- Zydus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Zydus Pharmaceuticals (USA), Inc. employs 1,273 people as of March 2026, showing workforce growth, with most employees in South Asia and Sales and Marketing as the fastest-growing functional group.
- Zydus Lifesciences Completes Acquisition of Assertio Holdings
Zydus Lifesciences acquired Assertio Holdings Inc. for US$23.50 per share to expand its presence in the US pharmaceutical market.
- Zydus Lifesciences beats estimates, sees high-teens growth in FY27
Zydus Lifesciences reported stronger-than-expected Q4FY26 financial results and projects high-teens revenue growth for FY27.
- Ruchir Umalkar appointed Vice President & Head of Tech Transfer at Zydus Group
Ruchir Umalkar was appointed Vice President & Head of Tech Transfer at Zydus Group.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Zydus Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies